{
    "info": {
        "nct_id": "NCT05672173",
        "official_title": "Phase 2 Study of the Combination of Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter's Transformation",
        "inclusion_criteria": "* Documented informed consent of the participant\n* Agreement for confirmatory pre-treatment tumor biopsy\n\n  * If a patient does not have an easily accessible lymph node to biopsy without excessive risk in the opinion of the investigator, archival biopsy material reviewed by a hematopathologist at the enrolling site for study eligibility and baseline correlatives may be acceptable with approval from the Study principal investigator (PI)\n* Age: >= 18 years\n* Eastern cooperative oncology group (ECOG) <= 2\n* Histologically confirmed Richter's Transformation (RT)\n* Relapsed / refractory following >=2 prior lines of systemic therapy; OR refractory to first-line chemoimmunotherapy; OR relapsed within 12 months of first line chemoimmunotherapy; OR relapsed after first line of chemoimmunotherapy and not eligible for hematopoietic stem cell transplantation due to comorbidities or age\n* Eligible to receive liso-cel and ibrutinib per package inserts\n* Fully recovered from the acute toxic effects (except alopecia) to <= Grade 1 to prior anti-cancer therapy\n* Absolute neutrophil count (ANC) >= 750/mm^3 unless there is bone marrow involvement\n* Platelets >= 75,000/mm^3 unless there is bone marrow involvement\n* Total bilirubin =< 1.5 X ULN (unless has Gilbert's disease)\n* Aspartate aminotransferase (AST) =< 2.5 x ULN\n* Alanine aminotransferase (ALT) =< 2.5 x ULN\n* Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula\n* International Normalized Ratio (INR) OR Prothrombin (PT) =< 1.5 x ULN\n* Activated Partial Thromboplastin Time (aPTT) =< 1.5 x ULN\n* Left ventricular ejection fraction (LVEF) >= 40%\n\n  * Note: To be performed within 28 days prior to Day 1 of protocol therapy.\n* Seronegative for HCV*, active HBV (Surface Antigen Negative), and syphilis (RPR)\n\n  * If positive, Hepatitis C RNA quantitation must be performed OR\n  * If seropositive for HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note: Infectious disease testing to be performed within 28 days prior to Day 1 of protocol therapy\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Subjects who previously received PD1 or PD-L1 inhibitor therapy\n* Autologous stem cell transplant within 3 months prior to Day 1 of protocol therapy\n* Allogeneic stem cell transplant within 3 months prior to Day 1 of protocol therapy and no active graft versus host disease (GVHD) or need for immunosuppressants\n* Chemotherapy, radiation therapy, immunotherapy within 14 days prior to Day 1 of protocol therapy\n* Strong CYP3A inducers within 14 days prior to Day 1 of protocol therapy\n* Warfarin within 5 days prior to Day 1 of protocol therapy\n* Current requirement for oxygen supplementation\n* Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (prednisone =< 7.5 mg /day or equivalent) is allowed throughout the study. Use of \"bridging\" steroids, to control disease, after leukapheresis and until 3 days prior to CAR T cell infusion, is allowed\n* Subjects with lymphoma only involving the central nervous system\n* Class III/IV cardiovascular disability according to the New York Heart Association (NYHA) Classification\n* Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of screening\n* Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, including seizure disorder\n* Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia\n* History of stroke or intracranial hemorrhage within 6 months prior to screening\n* History of other malignancies, except for malignancy surgically resected (or treated with other modalities) with curative intent, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer; malignancy treated with curative intent with no known active disease present for >= 3 years\n* Clinically significant uncontrolled illness\n* Active infection requiring antibiotics\n* Known history of immunodeficiency virus (HIV)\n* Females only: Pregnant or breastfeeding\n* Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment, well controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* International Normalized Ratio (INR) OR Prothrombin (PT) =< 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "International Normalized Ratio (INR) ... =< 1.5 x ULN",
                    "criterion": "International Normalized Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prothrombin (PT) ... =< 1.5 x ULN",
                    "criterion": "Prothrombin (PT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) >= 40%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= 40%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible to receive liso-cel and ibrutinib per package inserts",
            "criterions": [
                {
                    "exact_snippets": "Eligible to receive liso-cel ... per package inserts",
                    "criterion": "liso-cel eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility per package insert",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Eligible to receive ... ibrutinib per package inserts",
                    "criterion": "ibrutinib eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility per package insert",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 750/mm^3 unless there is bone marrow involvement",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 750/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 750,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless there is bone marrow involvement",
                    "criterion": "bone marrow involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If positive, Hepatitis C RNA quantitation must be performed OR",
            "criterions": [
                {
                    "exact_snippets": "If positive, Hepatitis C RNA quantitation must be performed",
                    "criterion": "Hepatitis C RNA quantitation",
                    "requirements": [
                        {
                            "requirement_type": "testing requirement",
                            "expected_value": "must be performed if positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a patient does not have an easily accessible lymph node to biopsy without excessive risk in the opinion of the investigator, archival biopsy material reviewed by a hematopathologist at the enrolling site for study eligibility and baseline correlatives may be acceptable with approval from the Study principal investigator (PI)",
            "criterions": [
                {
                    "exact_snippets": "patient does not have an easily accessible lymph node to biopsy without excessive risk in the opinion of the investigator",
                    "criterion": "lymph node accessibility for biopsy",
                    "requirements": [
                        {
                            "requirement_type": "accessibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "risk",
                            "expected_value": "excessive (in the opinion of the investigator)"
                        }
                    ]
                },
                {
                    "exact_snippets": "archival biopsy material reviewed by a hematopathologist at the enrolling site for study eligibility and baseline correlatives may be acceptable with approval from the Study principal investigator (PI)",
                    "criterion": "archival biopsy material",
                    "requirements": [
                        {
                            "requirement_type": "reviewed by hematopathologist at enrolling site",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "approval from Study principal investigator (PI)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Infectious disease testing to be performed within 28 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Infectious disease testing to be performed",
                    "criterion": "infectious disease testing",
                    "requirements": [
                        {
                            "requirement_type": "testing_performed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 28 days prior to Day 1 of protocol therapy",
                    "criterion": "infectious disease testing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "urine test is positive or cannot be confirmed as negative",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": [
                                "positive",
                                "cannot be confirmed as negative"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "a serum pregnancy test will be required",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 X ULN (unless has Gilbert's disease)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 X ULN (unless has Gilbert's disease)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless has Gilbert's disease",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 75,000/mm^3 unless there is bone marrow involvement",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 75,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 2.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 2.5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed / refractory following >=2 prior lines of systemic therapy; OR refractory to first-line chemoimmunotherapy; OR relapsed within 12 months of first line chemoimmunotherapy; OR relapsed after first line of chemoimmunotherapy and not eligible for hematopoietic stem cell transplantation due to comorbidities or age",
            "criterions": [
                {
                    "exact_snippets": "Relapsed / refractory following >=2 prior lines of systemic therapy",
                    "criterion": "disease status after prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        },
                        {
                            "requirement_type": "number of prior lines of systemic therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to first-line chemoimmunotherapy",
                    "criterion": "disease status after first-line chemoimmunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "refractory"
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed within 12 months of first line chemoimmunotherapy",
                    "criterion": "disease relapse timing after first-line chemoimmunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "relapsed"
                        },
                        {
                            "requirement_type": "time since first-line chemoimmunotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "relapsed after first line of chemoimmunotherapy and not eligible for hematopoietic stem cell transplantation due to comorbidities or age",
                    "criterion": "eligibility for hematopoietic stem cell transplantation after relapse post first-line chemoimmunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "status after first-line chemoimmunotherapy",
                            "expected_value": "relapsed"
                        },
                        {
                            "requirement_type": "hematopoietic stem cell transplantation eligibility",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "reason for ineligibility",
                            "expected_value": [
                                "comorbidities",
                                "age"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Meets other institutional and federal requirements for infectious disease titer requirements",
            "criterions": [
                {
                    "exact_snippets": "Meets other institutional and federal requirements for infectious disease titer requirements",
                    "criterion": "infectious disease titer",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": "meets institutional and federal requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age: >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months after the last dose of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months after the last dose of protocol therapy",
                    "criterion": "contraception or abstinence during and after study",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
            "criterions": [
                {
                    "exact_snippets": "not being surgically sterilized (men and women)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have not been free from menses for > 1 year (women only)",
                    "criterion": "menstrual status (women only)",
                    "requirements": [
                        {
                            "requirement_type": "time since last menses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement for confirmatory pre-treatment tumor biopsy",
            "criterions": [
                {
                    "exact_snippets": "Agreement for confirmatory pre-treatment tumor biopsy",
                    "criterion": "confirmatory pre-treatment tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seronegative for HCV*, active HBV (Surface Antigen Negative), and syphilis (RPR)",
            "criterions": [
                {
                    "exact_snippets": "Seronegative for HCV*",
                    "criterion": "HCV serostatus",
                    "requirements": [
                        {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active HBV (Surface Antigen Negative)",
                    "criterion": "HBV infection status",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "surface antigen",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "syphilis (RPR)",
                    "criterion": "syphilis (RPR) serostatus",
                    "requirements": [
                        {
                            "requirement_type": "seronegativity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern cooperative oncology group (ECOG) <= 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern cooperative oncology group (ECOG) <= 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If seropositive for HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable",
            "criterions": [
                {
                    "exact_snippets": "seropositive for HCV or HBV",
                    "criterion": "HCV or HBV seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nucleic acid quantitation must be performed",
                    "criterion": "nucleic acid quantitation for HCV or HBV",
                    "requirements": [
                        {
                            "requirement_type": "test performed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Viral load must be undetectable",
                    "criterion": "HCV or HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "viral load",
                            "expected_value": "undetectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Activated Partial Thromboplastin Time (aPTT) =< 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Activated Partial Thromboplastin Time (aPTT) =< 1.5 x ULN",
                    "criterion": "Activated Partial Thromboplastin Time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "24 hour urine test",
                                "Cockcroft-Gault formula"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented informed consent of the participant",
            "criterions": [
                {
                    "exact_snippets": "Documented informed consent of the participant",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 2.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 2.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed Richter's Transformation (RT)",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed Richter's Transformation (RT)",
                    "criterion": "Richter's Transformation (RT)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fully recovered from the acute toxic effects (except alopecia) to <= Grade 1 to prior anti-cancer therapy",
            "criterions": [
                {
                    "exact_snippets": "Fully recovered from the acute toxic effects (except alopecia) to <= Grade 1 to prior anti-cancer therapy",
                    "criterion": "acute toxic effects from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(except alopecia)",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Females only: Pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Females only",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment, well controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible",
            "criterions": [
                {
                    "exact_snippets": "active, known or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "type I diabetes mellitus ... are eligible",
                    "criterion": "type I diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypothyroidism only requiring hormone replacement ... are eligible",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "hormone replacement only"
                        }
                    ]
                },
                {
                    "exact_snippets": "skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment ... are eligible",
                    "criterion": "skin disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "not requiring systemic treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "well controlled asthma ... are eligible",
                    "criterion": "asthma",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "well controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "mild allergic rhinitis (seasonal allergies) ... are eligible",
                    "criterion": "allergic rhinitis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "mild"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant uncontrolled illness",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant uncontrolled illness",
                    "criterion": "clinically significant uncontrolled illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Class III/IV cardiovascular disability according to the New York Heart Association (NYHA) Classification",
            "criterions": [
                {
                    "exact_snippets": "Class III/IV cardiovascular disability according to the New York Heart Association (NYHA) Classification",
                    "criterion": "cardiovascular disability (NYHA Classification)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Class III",
                                "Class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring antibiotics",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring antibiotics",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring antibiotics"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with lymphoma only involving the central nervous system",
            "criterions": [
                {
                    "exact_snippets": "lymphoma only involving the central nervous system",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "central nervous system"
                        },
                        {
                            "requirement_type": "exclusivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's opinion of participant's compliance",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": "participant is able to comply"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Strong CYP3A inducers within 14 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Strong CYP3A inducers within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "use of strong CYP3A inducers",
                    "requirements": [
                        {
                            "requirement_type": "time window prior to Day 1 of protocol therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of stroke or intracranial hemorrhage within 6 months prior to screening",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 6 months prior to screening",
                    "criterion": "history of stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intracranial hemorrhage within 6 months prior to screening",
                    "criterion": "history of intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current requirement for oxygen supplementation",
            "criterions": [
                {
                    "exact_snippets": "Current requirement for oxygen supplementation",
                    "criterion": "oxygen supplementation",
                    "requirements": [
                        {
                            "requirement_type": "current requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia",
            "criterions": [
                {
                    "exact_snippets": "Known bleeding disorders (e.g., von Willebrand's disease)",
                    "criterion": "bleeding disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemophilia",
                    "criterion": "hemophilia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allogeneic stem cell transplant within 3 months prior to Day 1 of protocol therapy and no active graft versus host disease (GVHD) or need for immunosuppressants",
            "criterions": [
                {
                    "exact_snippets": "Allogeneic stem cell transplant within 3 months prior to Day 1 of protocol therapy",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no active graft versus host disease (GVHD)",
                    "criterion": "graft versus host disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "active disease",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no ... need for immunosuppressants",
                    "criterion": "immunosuppressant use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other malignancies, except for malignancy surgically resected (or treated with other modalities) with curative intent, basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer; malignancy treated with curative intent with no known active disease present for >= 3 years",
            "criterions": [
                {
                    "exact_snippets": "History of other malignancies",
                    "criterion": "history of other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for malignancy surgically resected (or treated with other modalities) with curative intent",
                    "criterion": "malignancy surgically resected (or treated with other modalities) with curative intent",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin",
                    "criterion": "basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-muscle invasive bladder cancer",
                    "criterion": "non-muscle invasive bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malignancy treated with curative intent with no known active disease present for >= 3 years",
                    "criterion": "malignancy treated with curative intent with no known active disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "active_disease_status",
                            "expected_value": "no known active disease"
                        },
                        {
                            "requirement_type": "disease_free_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects who previously received PD1 or PD-L1 inhibitor therapy",
            "criterions": [
                {
                    "exact_snippets": "previously received PD1 or PD-L1 inhibitor therapy",
                    "criterion": "PD1 or PD-L1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
            "criterions": [
                {
                    "exact_snippets": "history of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of immunodeficiency virus (HIV)",
            "criterions": [
                {
                    "exact_snippets": "Known history of immunodeficiency virus (HIV)",
                    "criterion": "immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Warfarin within 5 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Warfarin within 5 days prior to Day 1 of protocol therapy",
                    "criterion": "warfarin use",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures",
                    "criterion": "other condition contraindicating participation due to safety concerns",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety concern with clinical study procedures",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Autologous stem cell transplant within 3 months prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Autologous stem cell transplant within 3 months prior to Day 1 of protocol therapy",
                    "criterion": "autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, including seizure disorder",
            "criterions": [
                {
                    "exact_snippets": "known history or prior diagnosis of optic neuritis",
                    "criterion": "optic neuritis",
                    "requirements": [
                        {
                            "requirement_type": "history or prior diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunologic or inflammatory disease affecting the central nervous system",
                    "criterion": "immunologic or inflammatory disease affecting the central nervous system",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including seizure disorder",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement of steroids (prednisone =< 7.5 mg /day or equivalent) is allowed throughout the study. Use of \"bridging\" steroids, to control disease, after leukapheresis and until 3 days prior to CAR T cell infusion, is allowed",
            "criterions": [
                {
                    "exact_snippets": "Concurrent use of systemic steroids or chronic use of immunosuppressant medications.",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic use of immunosuppressant medications.",
                    "criterion": "immunosuppressant medication use",
                    "requirements": [
                        {
                            "requirement_type": "chronic use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Recent or current use of inhaled steroids is not exclusionary.",
                    "criterion": "inhaled steroid use",
                    "requirements": [
                        {
                            "requirement_type": "recent or current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Physiologic replacement of steroids (prednisone =< 7.5 mg /day or equivalent) is allowed throughout the study.",
                    "criterion": "physiologic steroid replacement (prednisone or equivalent)",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7.5,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of \"bridging\" steroids, to control disease, after leukapheresis and until 3 days prior to CAR T cell infusion, is allowed",
                    "criterion": "bridging steroid use after leukapheresis and until 3 days prior to CAR T cell infusion",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of screening",
            "criterions": [
                {
                    "exact_snippets": "clinically significant arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "arrhythmias not stable on medical management within two weeks of screening",
                    "criterion": "arrhythmia stability on medical management",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "reference_event",
                            "expected_value": "screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, radiation therapy, immunotherapy within 14 days prior to Day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation therapy ... within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy within 14 days prior to Day 1 of protocol therapy",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Note: To be performed within 28 days prior to Day 1 of protocol therapy.",
            "criterions": [
                {
                    "exact_snippets": "to be performed within 28 days prior to Day 1 of protocol therapy",
                    "criterion": "required assessments or procedures",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Day 1 of protocol therapy"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}